Fourth, fifth, and sixth derivatives of position

Basis Technologies and Jounce Media Automate Blocking of Ads on Low quality Websites

Retrieved on:

Thursday, November 9, 2023

Policy, Association of National Advertisers, MFA, RTB, DSP, Basis Technology, Marketing, Automation, Philosophy, Textile, Fourth, fifth, and sixth derivatives of position, Basis

CHICAGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Basis Technologies ( https://basis.com ), a global provider of programmatic advertising and media automation solutions, today announced automated protection preventing advertisers from serving ads on low quality websites.

Key Points:

CHICAGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Basis Technologies ( https://basis.com ), a global provider of programmatic advertising and media automation solutions, today announced automated protection preventing advertisers from serving ads on low quality websites.
The feature is powered by data from Jounce Media ( https://jouncemedia.com ), an industry leader in programmatic supply chain management.
Basis’ demand-side platform (DSP) is the first to use a dynamic exclusion list based on Jounce Media’s daily updating data to automatically block ads from being served on made-for-advertising (MFA) sites.
And because these sites demonstrate cost effective media metrics, programmatic media buyers often steer campaigns toward MFA publishers.

Kargo Is Industry’s Only Scaled 100% Premium SSP According To Jounce Media

Retrieved on:

Monday, September 18, 2023

Advertising network, MFA, Research, Investment, SSP, DSP, Renewable energy, Auction, Fourth, fifth, and sixth derivatives of position, Kargo

Kargo stands alone as the best inventory partner for brands looking to avoid sub-premium content.

Key Points:

Kargo stands alone as the best inventory partner for brands looking to avoid sub-premium content.
Kargo is the only scaled web SSP that ensures 100% of marketer investments trade through direct paths to premium supply,” said Chris Kane, Founder of Jounce.
As of early July, Jounce identified 19 SSPs including all major exchanges that had sales rights for at least 50% of premium web supply.
Among these, Jounce found, Kargo had the lowest exposure to sub-premium web supply:
This finding both validated Kargo’s commitment to premium supply and highlighted an opportunity to create the industry’s first 100% premium scaled SSP.

AIRNA Launches to Develop New Class of RNA Editing Therapeutics for Rare and Common Diseases

Retrieved on:

Tuesday, September 19, 2023

AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today emerged from stealth with a $30 million initial financing led by ARCH Venture Partners.

Key Points:

AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today emerged from stealth with a $30 million initial financing led by ARCH Venture Partners.
The financing enables AIRNA’s experienced team to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+TM.
“RNA editing is poised to lead the next generation of RNA therapeutics by targeting diseases not accessible through other approaches with a medicine that can be delivered to large patient populations,” said Kris Elverum, President and CEO of AIRNA.
“After making several technological improvements, I’m excited to see AIRNA advancing RNA editing therapeutics into precise medicines that could really impact patient’s lives.”
RNA editing is a disruptive therapeutic modality with unique potential to unlock the full promise of genetically defined medicines for rare and common diseases.

hC Bioscience Appoints Heather Hirsch, Ph.D. as SVP of Translational Science and Cancer Biology, Strengthening Leadership Team in Advancing tRNA-Based Therapeutics

Retrieved on:

Tuesday, July 18, 2023

Research fellow, Merck, Therapy, Fourth, fifth, and sixth derivatives of position, Senior, Medicine, Pharmaceutical industry, Telescopic sight

Boston, Massachusetts--(Newsfile Corp. - July 18, 2023) - hC Bioscience, a pioneering biotech company dedicated to advancing tRNA-based therapeutics, has appointed Heather Hirsch, Ph.D., as the Senior Vice President of Translational Science and Cancer Biology.

Key Points:

Boston, Massachusetts--(Newsfile Corp. - July 18, 2023) - hC Bioscience, a pioneering biotech company dedicated to advancing tRNA-based therapeutics, has appointed Heather Hirsch, Ph.D., as the Senior Vice President of Translational Science and Cancer Biology.
Hirsch, Ph.D. who will join a growing team of scientists, brings a wealth of experience and expertise, having served most recently as the Vice President of Clinical Translational Sciences at IMV Inc.
To view the full announcement, including downloadable images, bios, and more, click here .
Heather Hirsch, Ph.D. has been appointed as the Senior Vice President of Translational Science and Cancer Biology at hC Bioscience, bringing extensive experience and expertise in cancer biology and translational sciences from her previous roles at Merck, Jounce Therapeutics, and, IMV Inc.
hC Bioscience is dedicated to advancing tRNA-based therapeutics to target protein dysfunction and revolutionize the treatment of genetically defined conditions, which account for 10-15% of all human diseases.
Hirsch Ph.D. appointment reinforces hC Bioscience's commitment to attracting top talent in the industry and driving advancements in precision medicine, positioning the company as a leader in the field.

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

Retrieved on:

Monday, July 10, 2023

Duke University, Intellectual property, Central nervous system, CLO, General counsel, Biotechnology, Human, DSM-IV codes, Gilead, Boston University School of Law, Genzyme, Knee pain, Millennium, Corporation, Therapy, Neurology, Pharmaceutical industry, Voyager, Fourth, fifth, and sixth derivatives of position

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Jacquelyn Fahey Sandell as Chief Legal Officer (CLO).

Key Points:

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Jacquelyn Fahey Sandell as Chief Legal Officer (CLO).
Fahey Sandell brings more than 25 years of legal experience spanning in-house roles at multiple biotechnology and pharmaceutical companies.
She most recently served as CLO, Corporate Secretary, and Compliance Officer of Jounce Therapeutics, Inc.
“Jacqui’s breadth of expertise across securities, business development, regulatory, intellectual property, and multiple other legal disciplines makes her a strong addition to the growing Voyager team,” said Al Sandrock, M.D., Ph.D., Chief Executive Officer of Voyager.
Fahey Sandell previously held senior positions at Millennium: The Takeda Oncology Company and Genzyme Corporation, and she has worked at multiple top-tier law firms.

Jounce Therapeutics Announces Closing of Tender Offer

Retrieved on:

Thursday, May 4, 2023

Mergers and acquisitions, Concentra, Therapy, Acquisition, Eastern Time Zone, Holding company, Fourth, fifth, and sixth derivatives of position

The tender offer expired at 6:00 p.m., Eastern Time, on May 3, 2023.

Key Points:

The tender offer expired at 6:00 p.m., Eastern Time, on May 3, 2023.
As of the expiration of the offer, 36,367,727 shares of Jounce common stock had been validly tendered and not validly withdrawn from the tender offer, representing approximately 69.09% of the outstanding shares of Jounce common stock.
All conditions of the offer were satisfied or waived, and Concentra completed its acquisition of all outstanding shares of Jounce that were validly tendered and not validly withdrawn for the offer price.
Following the closing of the tender offer, Concentra Merger Sub merged with and into Jounce and all shares of Jounce common stock that had not been validly tendered were converted into the right to receive the same $1.85 per share in cash plus one CVR per share (the “Merger”).

Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc

Retrieved on:

Monday, April 3, 2023

NOT, FOR, Concentra, Acquisition, LAWS, Therapy, Holding company, Cryptocurrency, Fourth, fifth, and sixth derivatives of position

CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Redx Pharma plc ("Redx") have agreed to terminate their proposed business combination following the decision by Jounce’s Board of Directors to withdraw the recommendation for the all-share merger transaction with Redx (the "Redx Business Combination").

Key Points:

CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Redx Pharma plc ("Redx") have agreed to terminate their proposed business combination following the decision by Jounce’s Board of Directors to withdraw the recommendation for the all-share merger transaction with Redx (the "Redx Business Combination").
On March 27, 2023, Jounce notified Redx of the withdrawal of its recommendation in favor of the Redx Business Combination and termination of the co-operation agreement dated February 23, 2023 between Jounce and Redx.
Given that Jounce’s Board of Directors has withdrawn its recommendation to proceed with the Redx Business Combination, Jounce believes it is unlikely that Jounce stockholders would support the Redx Business Combination, which is a condition to closing the transaction.
As a result, Jounce will not be convening a Jounce meeting of stockholders to consider the Redx Business Combination.

Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

Retrieved on:

Monday, March 27, 2023

Workforce, NOT, AIM, CVR, FOR, Business, Concentra, Tail, Sale, Acquisition, LAWS, Patient, SELECT, LP, Therapy, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (“Concentra”) will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right (the “CVR”).

Key Points:

The $1.85 per share upfront consideration represents a premium of approximately 75% to Jounce’s closing share price immediately prior to the March 14, 2023 public disclosure of Concentra’s acquisition proposal.
Jounce’s Board of Directors is no longer recommending the proposed all-share merger transaction (the “Redx Business Combination”) with Redx Pharma Plc (AIM:REDX) (“Redx”).
In conjunction with the merger agreement, Jounce is implementing a workforce reduction of approximately 84% of its employees.
This reduction is expected to be completed within the next month and Jounce will incur restructuring costs totaling approximately $6.5 million1.

JNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders

Retrieved on:

Monday, March 27, 2023

Class Action Lawsuit, Professional Services, Legal, Concentra, Fraud, Advertising, Sale, Security (finance), Fourth, fifth, and sixth derivatives of position

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Jounce Therapeutics, Inc. (NASDAQ: JNCE) to Concentra Biosciences, LLC for $1.85 in cash per share plus a non-tradeable contingent value right is fair to Jounce shareholders.

Key Points:

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Jounce Therapeutics, Inc. (NASDAQ: JNCE) to Concentra Biosciences, LLC for $1.85 in cash per share plus a non-tradeable contingent value right is fair to Jounce shareholders.
On behalf of Jounce shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Moore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law Firm

Retrieved on:

Thursday, March 23, 2023

PLLC, Wall Street, Black Hawk, Fraud, Therapy, Centerbridge Partners, Security (finance), Bank, Fourth, fifth, and sixth derivatives of position

Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.

Key Points:

Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Moore Kuehn is a 5-star Google client-rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims.